83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes.

MLA

Martin Jimenez, M., et al. “83P Impact of Treatment Duration of Extended Adjuvant Therapy with Neratinib in Early Stage HER2+ HR+ Breast Cancer after Trastuzumab-Based Therapy on Patient Outcomes.” Annals of Oncology, vol. 31, May 2020, p. S43. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.03.023.

APA

Martin Jimenez, M., Gnant, M. I., Ejlertsen, B., Mansi, J. L., Ruiz-Borrego, M., Jakobsen, E. H., Osborne, C. K., Birhiray, R., Zhang, B., Wong, A., Moy, B., & Holmes, F. A. (2020). 83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes. Annals of Oncology, 31, S43. https://doi.org/10.1016/j.annonc.2020.03.023

Chicago

Martin Jimenez, M., M.I. Gnant, B. Ejlertsen, J.L. Mansi, M. Ruiz-Borrego, E.H. Jakobsen, C.K. Osborne, et al. 2020. “83P Impact of Treatment Duration of Extended Adjuvant Therapy with Neratinib in Early Stage HER2+ HR+ Breast Cancer after Trastuzumab-Based Therapy on Patient Outcomes.” Annals of Oncology 31 (May): S43. doi:10.1016/j.annonc.2020.03.023.